The Tissue Engineering-based Regeneration Products market is projected to grow at a CAGR of 9.17%, till 2035, claims Roots Analysis

The present treatment landscape of chronic wound and bone healing is characterized by a variety of unmet needs; tissue engineering-based regeneration products have emerged as a viable therapeutic option, which is capable of catering to the growing demand

Roots Analysis has announced the addition of “Tissue Engineering-based Regeneration Products Market, 2022-2035” report to its list of offerings.

Given the ever-increasing demand for tissue transplantation, primarily for wound and bone healing, there is an urgent need for safe and efficient products that enable healing and regeneration. At present, the supply of tissue donations is insufficient to satisfy the required demand. It is worth highlighting that, in recent years, tissue engineering and regenerative medicine have emerged as promising alternatives for tissue regeneration.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/tissue-engineering-market/request-sample.html

Key Market Insights

Over 115 tissue engineering-based skin regeneration products are presently available in this market space
About 50% of the total products are intended for wound healing, followed by developed for the purpose of surgical healing. Further, more than 50% of the products are made of human placental tissues, followed by those developed using other animal-based tissues.

~40 tissue engineering-based bone regeneration products are being offered by developers, globally
About 55% of the total products are made from bone tissues, followed by those developed using stem cells. In fact, most of the products are formulated in the form of a sheet (10), followed by those developed in the form of a bone matrix. Further, nearly 75% of the products are available in the form of xenografts.

Around 60 players are engaged in the development of the tissue engineering-based regeneration products
Majority of the players engaged in this domain are mid-sized firms (51-500 employees, 31%), followed by small players (11-51 employees, 27%), large players (1000-5000 employees, 26%) and very small (2-10 employees, 10%) companies. It is worth noting that ~40% developers are based in North America.

Till date, 750+ grants have been awarded for tissue engineering-based regeneration products
For research and development activity of tissue engineering-based regeneration products, grant amount of close to USD 300 million has been awarded in last five years. Further, 70% of this amount was awarded in 2021 alone.

Patent activity in this domain has grown at a CAGR of ~11%, between 2012 and 2022
R&D activity related to tissue engineering-based regeneration products is largely concentrated in North America; this can be validated from the fact that about 40% of the total patents were filed in this region, followed by the World Intellectual Property Organization (30%) and Asia-Pacific region (20%).

More than USD 2 billion Invested by industry and non-industry stakeholders in the last five years
Majority of the companies primarily received funding through private placements (~25%) and debt financing (~20%) rounds. It is worth mentioning that, over 95% of the amount was invested in companies based in North America.

Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2022
Large companies have inked the highest number of partnerships related to tissue engineering-based regeneration products, In addition nearly 40% majority of the agreements reported in tissue engineering market were instances of mergers and acquisitions.

North America is expected to capture more than 55% share in the tissue engineering-based regeneration products market by 2035
In terms of area of application, the current market is anticipated to be driven by products intended for skin healing (~50%), followed by those targeting bone healing (~30%). Further, xenograft-based products are expected to grow at a relatively faster pace (10.58%), till 2035.

Key Questions Answered
 Who are the leading players engaged in providing tissue engineering-based regeneration products?
 Which tissue engineering-based regeneration product is most commonly offered by developers?
 What is the relative competitiveness of tissue engineering-based regeneration product providers?
 What types of partnership models are commonly being adopted by stakeholders in this industry?
 What is the trend for capital investments in the tissue engineering-based regeneration products market?
 How has the patent landscape in this domain evolved over the last two decades?
 What is the overall trend of grant activity related to tissue engineering-based regeneration products?
 Which key market trends and driving factors are likely to impact the growth of the tissue engineering-based regeneration products market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the tissue engineering-based regeneration devices has been analyzed across the following segments:

 Type of Graft
 Allografts
 Autografts
 Xenografts

 Area of Application
 Bone Healing
 Burn Healing
 Wound Healing
 Surgical Healing
 Others

 Key Geographical Regions
 Ambulatory Surgical Centers
 Hospitals
 Specialty Clinics

 Key Geographical Regions
 North America
 Europe
 Asia
 Middle East and North Africa
 Latin America
 Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.
 AlloSource
 Bio-Tissue
 Integra LifeSciences
 MiMedx
 Organogenesis
 Smith+Nephew
 Tissue Regenix
 VIVEX Biologics

For additional details, please visit https://www.rootsanalysis.com/reports/tissue-engineering-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035



About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]
Roots Analysis has announced the addition of “Tissue Engineering-based Regeneration Products Market, 2022-2035” report to its list of offerings.

Given the ever-increasing demand for tissue transplantation, primarily for wound and bone healing, there is an urgent need for safe and efficient products that enable healing and regeneration. At present, the supply of tissue donations is insufficient to satisfy the required demand. It is worth highlighting that, in recent years, tissue engineering and regenerative medicine have emerged as promising alternatives for tissue regeneration.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/tissue-engineering-market/request-sample.html

Key Market Insights

Over 115 tissue engineering-based skin regeneration products are presently available in this market space
About 50% of the total products are intended for wound healing, followed by developed for the purpose of surgical healing. Further, more than 50% of the products are made of human placental tissues, followed by those developed using other animal-based tissues.

~40 tissue engineering-based bone regeneration products are being offered by developers, globally
About 55% of the total products are made from bone tissues, followed by those developed using stem cells. In fact, most of the products are formulated in the form of a sheet (10), followed by those developed in the form of a bone matrix. Further, nearly 75% of the products are available in the form of xenografts.

Around 60 players are engaged in the development of the tissue engineering-based regeneration products
Majority of the players engaged in this domain are mid-sized firms (51-500 employees, 31%), followed by small players (11-51 employees, 27%), large players (1000-5000 employees, 26%) and very small (2-10 employees, 10%) companies. It is worth noting that ~40% developers are based in North America.

Till date, 750+ grants have been awarded for tissue engineering-based regeneration products
For research and development activity of tissue engineering-based regeneration products, grant amount of close to USD 300 million has been awarded in last five years. Further, 70% of this amount was awarded in 2021 alone.

Patent activity in this domain has grown at a CAGR of ~11%, between 2012 and 2022
R&D activity related to tissue engineering-based regeneration products is largely concentrated in North America; this can be validated from the fact that about 40% of the total patents were filed in this region, followed by the World Intellectual Property Organization (30%) and Asia-Pacific region (20%).

More than USD 2 billion Invested by industry and non-industry stakeholders in the last five years
Majority of the companies primarily received funding through private placements (~25%) and debt financing (~20%) rounds. It is worth mentioning that, over 95% of the amount was invested in companies based in North America.

Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2022
Large companies have inked the highest number of partnerships related to tissue engineering-based regeneration products, In addition nearly 40% majority of the agreements reported in tissue engineering market were instances of mergers and acquisitions.

North America is expected to capture more than 55% share in the tissue engineering-based regeneration products market by 2035
In terms of area of application, the current market is anticipated to be driven by products intended for skin healing (~50%), followed by those targeting bone healing (~30%). Further, xenograft-based products are expected to grow at a relatively faster pace (10.58%), till 2035.

Key Questions Answered
 Who are the leading players engaged in providing tissue engineering-based regeneration products?
 Which tissue engineering-based regeneration product is most commonly offered by developers?
 What is the relative competitiveness of tissue engineering-based regeneration product providers?
 What types of partnership models are commonly being adopted by stakeholders in this industry?
 What is the trend for capital investments in the tissue engineering-based regeneration products market?
 How has the patent landscape in this domain evolved over the last two decades?
 What is the overall trend of grant activity related to tissue engineering-based regeneration products?
 Which key market trends and driving factors are likely to impact the growth of the tissue engineering-based regeneration products market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the tissue engineering-based regeneration devices has been analyzed across the following segments:

 Type of Graft
 Allografts
 Autografts
 Xenografts

 Area of Application
 Bone Healing
 Burn Healing
 Wound Healing
 Surgical Healing
 Others

 Key Geographical Regions
 Ambulatory Surgical Centers
 Hospitals
 Specialty Clinics

 Key Geographical Regions
 North America
 Europe
 Asia
 Middle East and North Africa
 Latin America
 Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.
 AlloSource
 Bio-Tissue
 Integra LifeSciences
 MiMedx
 Organogenesis
 Smith+Nephew
 Tissue Regenix
 VIVEX Biologics

For additional details, please visit https://www.rootsanalysis.com/reports/tissue-engineering-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035



About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

Roots Analysis has announced the addition of “Tissue Engineering-based Regeneration Products Market, 2022-2035” report to its list of offerings.

Given the ever-increasing demand for tissue transplantation, primarily for wound and bone healing, there is an urgent need for safe and efficient products that enable healing and regeneration. At present, the supply of tissue donations is insufficient to satisfy the required demand. It is worth highlighting that, in recent years, tissue engineering and regenerative medicine have emerged as promising alternatives for tissue regeneration.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/tissue-engineering-market/request-sample.html

Key Market Insights

Over 115 tissue engineering-based skin regeneration products are presently available in this market space
About 50% of the total products are intended for wound healing, followed by developed for the purpose of surgical healing. Further, more than 50% of the products are made of human placental tissues, followed by those developed using other animal-based tissues.

~40 tissue engineering-based bone regeneration products are being offered by developers, globally
About 55% of the total products are made from bone tissues, followed by those developed using stem cells. In fact, most of the products are formulated in the form of a sheet (10), followed by those developed in the form of a bone matrix. Further, nearly 75% of the products are available in the form of xenografts.

Around 60 players are engaged in the development of the tissue engineering-based regeneration products
Majority of the players engaged in this domain are mid-sized firms (51-500 employees, 31%), followed by small players (11-51 employees, 27%), large players (1000-5000 employees, 26%) and very small (2-10 employees, 10%) companies. It is worth noting that ~40% developers are based in North America.

Till date, 750+ grants have been awarded for tissue engineering-based regeneration products
For research and development activity of tissue engineering-based regeneration products, grant amount of close to USD 300 million has been awarded in last five years. Further, 70% of this amount was awarded in 2021 alone.

Patent activity in this domain has grown at a CAGR of ~11%, between 2012 and 2022
R&D activity related to tissue engineering-based regeneration products is largely concentrated in North America; this can be validated from the fact that about 40% of the total patents were filed in this region, followed by the World Intellectual Property Organization (30%) and Asia-Pacific region (20%).

More than USD 2 billion Invested by industry and non-industry stakeholders in the last five years
Majority of the companies primarily received funding through private placements (~25%) and debt financing (~20%) rounds. It is worth mentioning that, over 95% of the amount was invested in companies based in North America.

Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2022
Large companies have inked the highest number of partnerships related to tissue engineering-based regeneration products, In addition nearly 40% majority of the agreements reported in tissue engineering market were instances of mergers and acquisitions.

North America is expected to capture more than 55% share in the tissue engineering-based regeneration products market by 2035
In terms of area of application, the current market is anticipated to be driven by products intended for skin healing (~50%), followed by those targeting bone healing (~30%). Further, xenograft-based products are expected to grow at a relatively faster pace (10.58%), till 2035.

Key Questions Answered
 Who are the leading players engaged in providing tissue engineering-based regeneration products?
 Which tissue engineering-based regeneration product is most commonly offered by developers?
 What is the relative competitiveness of tissue engineering-based regeneration product providers?
 What types of partnership models are commonly being adopted by stakeholders in this industry?
 What is the trend for capital investments in the tissue engineering-based regeneration products market?
 How has the patent landscape in this domain evolved over the last two decades?
 What is the overall trend of grant activity related to tissue engineering-based regeneration products?
 Which key market trends and driving factors are likely to impact the growth of the tissue engineering-based regeneration products market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the tissue engineering-based regeneration devices has been analyzed across the following segments:

 Type of Graft
 Allografts
 Autografts
 Xenografts

 Area of Application
 Bone Healing
 Burn Healing
 Wound Healing
 Surgical Healing
 Others

 Key Geographical Regions
 Ambulatory Surgical Centers
 Hospitals
 Specialty Clinics

 Key Geographical Regions
 North America
 Europe
 Asia
 Middle East and North Africa
 Latin America
 Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.
 AlloSource
 Bio-Tissue
 Integra LifeSciences
 MiMedx
 Organogenesis
 Smith+Nephew
 Tissue Regenix
 VIVEX Biologics

For additional details, please visit https://www.rootsanalysis.com/reports/tissue-engineering-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035



About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

Roots Analysis has announced the addition of “Tissue Engineering-based Regeneration Products Market, 2022-2035” report to its list of offerings.

Given the ever-increasing demand for tissue transplantation, primarily for wound and bone healing, there is an urgent need for safe and efficient products that enable healing and regeneration. At present, the supply of tissue donations is insufficient to satisfy the required demand. It is worth highlighting that, in recent years, tissue engineering and regenerative medicine have emerged as promising alternatives for tissue regeneration.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/tissue-engineering-market/request-sample.html

Key Market Insights

Over 115 tissue engineering-based skin regeneration products are presently available in this market space
About 50% of the total products are intended for wound healing, followed by developed for the purpose of surgical healing. Further, more than 50% of the products are made of human placental tissues, followed by those developed using other animal-based tissues.

~40 tissue engineering-based bone regeneration products are being offered by developers, globally
About 55% of the total products are made from bone tissues, followed by those developed using stem cells. In fact, most of the products are formulated in the form of a sheet (10), followed by those developed in the form of a bone matrix. Further, nearly 75% of the products are available in the form of xenografts.

Around 60 players are engaged in the development of the tissue engineering-based regeneration products
Majority of the players engaged in this domain are mid-sized firms (51-500 employees, 31%), followed by small players (11-51 employees, 27%), large players (1000-5000 employees, 26%) and very small (2-10 employees, 10%) companies. It is worth noting that ~40% developers are based in North America.

Till date, 750+ grants have been awarded for tissue engineering-based regeneration products
For research and development activity of tissue engineering-based regeneration products, grant amount of close to USD 300 million has been awarded in last five years. Further, 70% of this amount was awarded in 2021 alone.

Patent activity in this domain has grown at a CAGR of ~11%, between 2012 and 2022
R&D activity related to tissue engineering-based regeneration products is largely concentrated in North America; this can be validated from the fact that about 40% of the total patents were filed in this region, followed by the World Intellectual Property Organization (30%) and Asia-Pacific region (20%).

More than USD 2 billion Invested by industry and non-industry stakeholders in the last five years
Majority of the companies primarily received funding through private placements (~25%) and debt financing (~20%) rounds. It is worth mentioning that, over 95% of the amount was invested in companies based in North America.

Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2022
Large companies have inked the highest number of partnerships related to tissue engineering-based regeneration products, In addition nearly 40% majority of the agreements reported in tissue engineering market were instances of mergers and acquisitions.

North America is expected to capture more than 55% share in the tissue engineering-based regeneration products market by 2035
In terms of area of application, the current market is anticipated to be driven by products intended for skin healing (~50%), followed by those targeting bone healing (~30%). Further, xenograft-based products are expected to grow at a relatively faster pace (10.58%), till 2035.

Key Questions Answered
 Who are the leading players engaged in providing tissue engineering-based regeneration products?
 Which tissue engineering-based regeneration product is most commonly offered by developers?
 What is the relative competitiveness of tissue engineering-based regeneration product providers?
 What types of partnership models are commonly being adopted by stakeholders in this industry?
 What is the trend for capital investments in the tissue engineering-based regeneration products market?
 How has the patent landscape in this domain evolved over the last two decades?
 What is the overall trend of grant activity related to tissue engineering-based regeneration products?
 Which key market trends and driving factors are likely to impact the growth of the tissue engineering-based regeneration products market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the tissue engineering-based regeneration devices has been analyzed across the following segments:

 Type of Graft
 Allografts
 Autografts
 Xenografts

 Area of Application
 Bone Healing
 Burn Healing
 Wound Healing
 Surgical Healing
 Others

 Key Geographical Regions
 Ambulatory Surgical Centers
 Hospitals
 Specialty Clinics

 Key Geographical Regions
 North America
 Europe
 Asia
 Middle East and North Africa
 Latin America
 Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.
 AlloSource
 Bio-Tissue
 Integra LifeSciences
 MiMedx
 Organogenesis
 Smith+Nephew
 Tissue Regenix
 VIVEX Biologics

For additional details, please visit https://www.rootsanalysis.com/reports/tissue-engineering-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035



About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

Roots Analysis has announced the addition of “Tissue Engineering-based Regeneration Products Market, 2022-2035” report to its list of offerings.

Given the ever-increasing demand for tissue transplantation, primarily for wound and bone healing, there is an urgent need for safe and efficient products that enable healing and regeneration. At present, the supply of tissue donations is insufficient to satisfy the required demand. It is worth highlighting that, in recent years, tissue engineering and regenerative medicine have emerged as promising alternatives for tissue regeneration.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/tissue-engineering-market/request-sample.html

Key Market Insights

Over 115 tissue engineering-based skin regeneration products are presently available in this market space
About 50% of the total products are intended for wound healing, followed by developed for the purpose of surgical healing. Further, more than 50% of the products are made of human placental tissues, followed by those developed using other animal-based tissues.

~40 tissue engineering-based bone regeneration products are being offered by developers, globally
About 55% of the total products are made from bone tissues, followed by those developed using stem cells. In fact, most of the products are formulated in the form of a sheet (10), followed by those developed in the form of a bone matrix. Further, nearly 75% of the products are available in the form of xenografts.

Around 60 players are engaged in the development of the tissue engineering-based regeneration products
Majority of the players engaged in this domain are mid-sized firms (51-500 employees, 31%), followed by small players (11-51 employees, 27%), large players (1000-5000 employees, 26%) and very small (2-10 employees, 10%) companies. It is worth noting that ~40% developers are based in North America.

Till date, 750+ grants have been awarded for tissue engineering-based regeneration products
For research and development activity of tissue engineering-based regeneration products, grant amount of close to USD 300 million has been awarded in last five years. Further, 70% of this amount was awarded in 2021 alone.

Patent activity in this domain has grown at a CAGR of ~11%, between 2012 and 2022
R&D activity related to tissue engineering-based regeneration products is largely concentrated in North America; this can be validated from the fact that about 40% of the total patents were filed in this region, followed by the World Intellectual Property Organization (30%) and Asia-Pacific region (20%).

More than USD 2 billion Invested by industry and non-industry stakeholders in the last five years
Majority of the companies primarily received funding through private placements (~25%) and debt financing (~20%) rounds. It is worth mentioning that, over 95% of the amount was invested in companies based in North America.

Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2022
Large companies have inked the highest number of partnerships related to tissue engineering-based regeneration products, In addition nearly 40% majority of the agreements reported in tissue engineering market were instances of mergers and acquisitions.

North America is expected to capture more than 55% share in the tissue engineering-based regeneration products market by 2035
In terms of area of application, the current market is anticipated to be driven by products intended for skin healing (~50%), followed by those targeting bone healing (~30%). Further, xenograft-based products are expected to grow at a relatively faster pace (10.58%), till 2035.

Key Questions Answered
 Who are the leading players engaged in providing tissue engineering-based regeneration products?
 Which tissue engineering-based regeneration product is most commonly offered by developers?
 What is the relative competitiveness of tissue engineering-based regeneration product providers?
 What types of partnership models are commonly being adopted by stakeholders in this industry?
 What is the trend for capital investments in the tissue engineering-based regeneration products market?
 How has the patent landscape in this domain evolved over the last two decades?
 What is the overall trend of grant activity related to tissue engineering-based regeneration products?
 Which key market trends and driving factors are likely to impact the growth of the tissue engineering-based regeneration products market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the tissue engineering-based regeneration devices has been analyzed across the following segments:

 Type of Graft
 Allografts
 Autografts
 Xenografts

 Area of Application
 Bone Healing
 Burn Healing
 Wound Healing
 Surgical Healing
 Others

 Key Geographical Regions
 Ambulatory Surgical Centers
 Hospitals
 Specialty Clinics

 Key Geographical Regions
 North America
 Europe
 Asia
 Middle East and North Africa
 Latin America
 Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.
 AlloSource
 Bio-Tissue
 Integra LifeSciences
 MiMedx
 Organogenesis
 Smith+Nephew
 Tissue Regenix
 VIVEX Biologics

For additional details, please visit https://www.rootsanalysis.com/reports/tissue-engineering-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035



About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]